◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC

CIK: 1730430 SIC: 2834
$597.97M
Revenue
$35.92M
Net Income
87.52%
Gross Margin
6.38%
Op. Margin
$174.11M
Free Cash Flow
Financial Statements Annual (10-K)
Showing 4 of 7 annual reports available (2018 - 2024)
Breakdown TTM
(Sep 30, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
+ Total Revenue $597.97M $423.24M $270.26M $220.18M $38.54M
Revenue Growth % 41.3% 56.6% 22.7% 471.2% nan%
Cost of Revenue $74.62M $60.91M $33.41M $22.89M $9.10M
+ Gross Profit $523.35M $362.33M $236.85M $197.28M $29.44M
Gross Margin % 87.5% 85.6% 87.6% 89.6% 76.4%
Research & Development $97.46M $111.62M $76.10M $65.49M $99.30M
Selling General & Admin $180.03M $168.01M $129.43M $97.95M $85.95M
+ Operating Income $38.15M $-45.62M $-25.20M $9.77M $-156.64M
Operating Margin % 6.4% -10.8% -9.3% 4.4% -406.4%
Interest Income - $9.04M $8.23M - $97.00K
Income Before Tax $48.62M $-36.15M $-16.65M $11.03M $-156.54M
Income Tax Expense $12.70M $7.04M $-30.74M $-172.34M $1.39M
+ Net Income $35.92M $-43.19M $14.08M $183.36M $-157.92M
Net Margin % 6.0% -10.2% 5.2% 83.3% -409.7%
Basic EPS 0.49 -0.60 0.20 2.64 -2.30
Diluted EPS 0.45 -0.60 0.20 2.60 -2.30
Basic Shares Outstanding 74.7M 71.4M 70.1M 69.4M 68.6M
Diluted Shares Outstanding 80.0M 71.4M 71.9M 70.4M 68.6M
Breakdown FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
Cash & Cash Equivalents $183.58M $107.95M $122.72M $122.47M
Short-term Investments $60.05M $98.42M $67.89M $59.73M
Accounts Receivable $41.72M $21.27M $12.66M $3.98M
Inventory $26.36M $31.12M $21.60M $3.67M
Other Current Assets $20.08M $17.54M $10.54M $6.58M
Total Current Assets $331.80M $276.30M $243.06M $196.45M
Property Plant & Equipment $662.00K $734.00K $1.66M $2.83M
Intangible Assets $16.25M $17.25M $18.25M $19.25M
Other Non-current Assets $10.31M $827.00K $5.82M $8.72M
Total Assets $580.55M $526.32M $459.67M $232.80M
Accounts Payable $2.04M $8.25M $7.90M $1.87M
Accrued Liabilities $32.35M $44.67M $30.11M $38.03M
Deferred Revenue - $307.00K - -
Other Current Liabilities $16.08M $8.19M $5.75M $1.54M
Total Current Liabilities $100.62M $63.67M $47.07M $44.82M
Other Non-current Liabilities $1.82M $1.86M $1.84M $270.00K
Total Liabilities $142.12M $87.48M $63.52M $47.76M
Retained Earnings $-521.14M $-477.95M $-492.03M $-675.40M
Total Stockholders Equity $438.44M $438.84M $396.15M $185.04M
Total Liabilities & Equity $580.55M $526.32M $459.67M $232.80M
Breakdown TTM
(Sep 30, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
Net Income $44.46M $-43.19M $14.08M $183.36M $-157.92M
Depreciation & Amortization $2.54M $1.70M $2.34M $2.40M $2.35M
Stock-based Compensation $42.81M $30.69M $27.15M $25.12M $25.17M
Deferred Income Tax $9.69M $8.13M $-33.79M $-185.50M $11.00K
Change in Receivables $15.38M $20.46M $8.61M $8.68M $3.91M
Change in Inventory $30.24M $-4.76M $9.52M $17.92M $3.67M
Change in Payables $5.03M $-6.31M $347.00K $6.03M $1.37M
Operating Cash Flow $175.60M $25.69M $13.30M $5.81M $-126.30M
Capital Expenditure $1.49M $277.00K $130.00K $105.00K $415.00K
Investing Cash Flow $-159.85M $37.67M $-29.56M $-8.08M $128.63M
Financing Cash Flow $43.74M $12.27M $1.50M $2.52M $5.88M
SEC Filing Format - Data shown as it appears in the Q3 2025 (10-Q) filing Period ended: Sep 30, 2025
Condensed Consolidated Statements of Operations
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Total Revenue $180.85M - $475.44M -
Cost of Revenue $20.26M - $56.73M -
Research & Development $24.17M - $62.24M -
Selling General & Admin $49.10M - $139.50M -
Operating Income $24.02M - $57.45M -
Income Before Tax $27.16M - $65.60M -
Income Tax Expense $8.72M - $20.79M -
Net Income $18.43M $-3.91M $44.81M -
Basic EPS 0.25 - 0.61 -
Diluted EPS 0.23 - 0.57 -
Basic Shares Outstanding $74.71M - $73.61M -
Diluted Shares Outstanding $80.04M - $78.03M -
Condensed Consolidated Balance Sheets
Description Sep 30, 2025 Dec 31, 2024
Cash & Cash Equivalents $174.86M $183.58M
Short-term Investments $177.24M $60.05M
Accounts Receivable $51.74M $41.72M
Inventory $41.40M $26.36M
Other Current Assets $30.29M $20.08M
Total Current Assets $475.53M $331.80M
Property Plant & Equipment $1.66M $662.00K
Intangible Assets $15.50M $16.25M
Other Non-current Assets $8.29M $10.31M
Total Assets $712.33M $580.55M
Accounts Payable $6.15M $2.04M
Accrued Liabilities $30.94M $32.35M
Other Current Liabilities $20.52M $16.08M
Total Current Liabilities $123.59M $100.62M
Other Non-current Liabilities $14.53M $1.82M
Total Liabilities $176.95M $142.12M
Retained Earnings $-476.34M $-521.14M
Total Stockholders Equity $535.38M $438.44M
Total Liabilities & Equity $712.33M $580.55M
Condensed Consolidated Statements of Cash Flows
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Net Income $18.43M $-3.91M $44.81M -
Depreciation & Amortization - - $1.09M -
Stock-based Compensation $10.14M - $26.77M -
Deferred Income Tax $4.23M - $9.86M -
Change in Receivables - - $10.02M -
Change in Inventory - - $15.03M -
Change in Payables - - $4.26M -
Operating Cash Flow - - $84.09M -
Capital Expenditure - - $935.00K -
Investing Cash Flow - - $-118.18M -
Financing Cash Flow - - $25.36M -

All values are in USD (United States Dollars). Data is sourced from SEC EDGAR 10-K filings.

Annual data represents full fiscal year results. FY = Fiscal Year ending.

NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...